Archive for November 2022
Firebrick’s international trial gets radio spotlight
30 Nov 2022
Executive Chairman Peter Molloy speaks with 3BA Radio about Firebrick’s international trial targeting the common cold.
Nasodine composition patent accepted in Australia
14 Nov 2022
Firebrick Pharma Limited is pleased to announce that a patent covering the unique formulation of Nasodine® Nasal Spray has been accepted in Australia.
Update on Nasodine Phase 3 trial
02 Nov 2022
Firebrick Pharma is pleased to provide an update on our Phase 3 clinical trial of Nasodine® Nasal Spray in the treatment of the common cold. As at 31 October, the trial has so far successfully recruited 224 subjects with early-stage colds into the ITT (‘Intent-To-Treat’ population), with an estimated 100 qualifying for the primary endpoint…